Search clinical trials for: Peginterferon beta-1a

Total 6893 results

Biogen

Completed

Pharmacokinetic Study of Peginterferon Beta-1a in Japanese and Caucasian Adult Healthy Participants.

Healthy

United Kingdom
Biogen

Completed

Peginterferon Beta-1a (BIIB017) Autoinjector Pharmacokinetic Study in Healthy Volunteers

Multiple Sclerosis | Healthy

United States
Biogen

Completed

Plegridy Satisfaction Study in Participants (PLATINUM)

Relapsing-Remitting Multiple Sclerosis (RRMS)

Italy
Biogen

Completed

A Single-Dose, Pharmacokinetic/Pharmacodynamic (PK/PD), & Safety Study of BIIB017 in Participants With Renal Impairment & Healthy Volunteers

Healthy | Renal Insufficiency
Pontificia Universidad Catolica de Chile
Telethon Kids Institute

Completed

The Containing Coronavirus Disease 19 (COVID-19) Trial (ConCorD-19)

Covid19 | SARS-CoV Infection | Interferon

Chile
Biogen

Completed

Plegridy Observational Program (POP)

Relapsing Forms of Multiple Sclerosis

United States, Italy, Switzerland, Canada, Australia, Germany, Spain, France, Portugal, Netherlands, United Kingdom, Denmark, Austria, Ireland
Biogen

Completed

Long-Term Safety and Efficacy Study of Peginterferon Beta-1a (ATTAIN)

Relapsing Multiple Sclerosis

United States, Croatia, Russian Federation, India, Spain, New Zealand, Canada, Belgium, Netherlands, Bulgaria, Serbia, Greece, Ukraine, Mexico, Georgia, Colombia, Germany, Poland, United Kingdom, Czech Republic, France, Chile, Romania, Eston... and more
Stanford University

Completed

Single-Blind Study of a Single Dose of Peginterferon Lambda-1a Compared With Placebo in Outpatients With Mild COVID-19 (COVID-Lambda)

COVID-19

United States
Biogen

Completed

Evaluate Safety/Tolerability in Portuguese Participants With RRMS Transitioning From Current Therapy (PLENO)

Relapsing Remitting Multiple Sclerosis

Portugal
Biogen

Completed

Study to Evaluate the Pharmacokinetic Profiles of BIIB017 (Peginterferon Beta-1a) and Rebif® (Interferon Beta-1a) in Healthy Volunteers

Multiple Sclerosis

United States
Biogen

Completed

Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis (ADVANCE)

Relapsing Multiple Sclerosis

United States, Germany, Russian Federation, India, New Zealand, Spain, Belgium, Colombia, Canada, Bulgaria, Serbia, Greece, Peru, Ukraine, Poland, United Kingdom, Croatia, France, Romania, Chile, Czech Republic, Mexico, Estonia, Georgia, Latv... and more
Biogen

Withdrawn

Transition to Peginterferon Beta-1a (BIIB017) From Subcutaneous Interferon Therapy (Frequency)

Relapsing Multiple Sclerosis
Biogen

Recruiting

A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis

Multiple Sclerosis, Relapsing-Remitting

Spain, Germany, Croatia, Turkey, Saudi Arabia, Hungary, Belgium, Australia, France, Portugal, Slovakia, United States, Bulgaria, Greece, Kuwait, Russian Federation, Tunisia, Italy, Argentina, Czechia, Israel, Serbia
Food and Drug Administration (FDA)
Spaulding Clinical Research LLC

Completed

Pharmacodynamic Biomarkers to Support Biosimilar Development: Interferon Beta-1A Products

Healthy Subjects | Pharmacokinetics | Pharmacodynamics

United States
Bristol-Myers Squibb

Completed

Three-year Follow-up Study of Subjects Who Participated in a Previous Lambda (BMS-914143) Chronic Hepatitis C Clinical Trial

Hepatitis C

Argentina, Australia, Belgium, France, Germany, Italy, United States, Canada, Spain, Mexico, Austria, Poland, Netherlands, Korea, Republic of, Puerto Rico, New Zealand, Finland, Greece, Romania
Biogen
AMS Advanced Medical Services GmbH

Completed

A Post-Authorization Safety Study of Interferon Beta Therapy in Participants With Multiple Sclerosis (PERFECT)

Multiple Sclerosis, Relapsing-Remitting

Germany
Bayer
Novartis Pharmaceuticals; Biogen; EPID Research; Merck Serono Europe Ltd

Completed

EPID Multiple Sclerosis Pregnancy Study

Multiple Sclerosis

Finland
Biogen

Withdrawn

Brimonidine Tartrate for the Treatment of Injection Related Erythema (BRITE)

Relapsing-Remitting Multiple Sclerosis (RRMS)
Bristol-Myers Squibb

Completed

Pharmacokinetic Study of BMS-914143 in Participants With Normal Renal Function and Mild, Moderate, Severe and End-stage Renal Dysfunction (PK)

Chronic Hepatitis C Virus Infection | Chronic Hepatitis B Virus Infection

United States
Biocad

Completed

Study of Efficacy and Safety of Drugs BCD-033 and Rebif for Treatment of Patients With Multiple Sclerosis

Multiple Sclerosis

Russian Federation
Centre Hospitalier Universitaire Vaudois
BioPartners GmbH

Completed

Phase I BP Interferon (IFN) Beta-004

Multiple Sclerosis, Relapsing-Remitting
Cinnagen

Completed

Efficacy and Safety of Peginterferon Beta-1a (CinnaGen) in Participants With Relapsing Remitting Multiple Sclerosis

Relapsing Remitting Multiple Sclerosis (RRMS)

Iran, Islamic Republic of
Eiger BioPharmaceuticals

Completed

A Study to Evaluate Pegylated Interferon Lambda Monotherapy in Patients With Chronic Hepatitis Delta Virus Infection (LIMT)

Hepatitis D, Chronic

Israel, New Zealand, Pakistan
Merck KGaA, Darmstadt, Germany

Completed

A Study to Evaluate Rebif® New Formulation (Interferon-beta-1a) in Relapsing Remitting Multiple Sclerosis (IMPROVE)

Multiple Sclerosis, Relapsing-Remitting
Biocad

Completed

Open Label Study of Tolerability, Pharmacokinetics and Pharmacodynamics of BCD-054 (Pegylated Interferon Beta-1a), IM and SC, Compared to Rebif® and Avonex® in Healthy Volunteers

Healthy

Russian Federation
Valneva Austria GmbH

Recruiting

Phase 1 Trial to Assess the Safety and Immunogenicity of an Inactivated, Adjuvanted Whole Zika Virus Vaccine Candidate (VLA1601) in Healthy Adults

Zika | Zika Virus Infection

United States
Biogen

Terminated

Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants

Multiple Sclerosis, Relapsing-Remitting

Mexico, Turkey, United States, Hungary, Taiwan, Thailand, Korea, Republic of, Saudi Arabia, Malaysia, Colombia, Estonia, Jordan, Tunisia
Biogen

Completed

Biogen Multiple Sclerosis Pregnancy Exposure Registry

Multiple Sclerosis | Exposure During Pregnancy

Spain, Italy, Australia, Poland, United Kingdom, United States, Canada, France, Germany, Ireland
Merck KGaA, Darmstadt, Germany

Completed

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment (SOLAR)

Relapsing-Remitting Multiple Sclerosis

Germany, Estonia, Latvia, Lithuania, Finland, Austria, Denmark, Netherlands, Portugal, Switzerland, Norway, Italy
EMD Serono
Merck Serono International SA

Completed

Safety and Efficacy of Interferon-Beta-1a (Rebif®) for Treating Subjects With Acute Symptoms of Ulcerative Colitis

Ulcerative Colitis

Sweden, Germany, Netherlands, Israel, Singapore, Switzerland, United Kingdom
EMD Serono
Merck Pte. Ltd., Singapore

Completed

A Multicenter Phase 3 Study of Interferon-beta-1a for the Treatment of Chronic Hepatitis C in Asian Subjects

Hepatitis C
Eiger BioPharmaceuticals

Active, not recruiting

Phase 3 Study to Evaluate the Efficacy and Safety of Peginterferon Lambda for 48 Weeks in Patients With Chronic HDV (LIMT-2)

Hepatitis Delta Virus

United States, France, Belgium, Spain, Italy, Turkey, Bulgaria, Germany, Israel, Romania, Georgia, Moldova, Republic of
Biogen

Completed

Characterize Flu-like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Non-Pegylated Interferon Beta (IFN-β) Therapies to Peginterferon Beta-1a (BIIB017) (ALLOW)

Relapsing Multiple Sclerosis

United States
Biocad

Completed

Comparative Clinical Trial to Evaluate Efficacy, Safety and Tolerance of BCD-054 and Avonex® for Treatment of Patients With Remitting-relapsing Multiple Sclerosis

Multiple Sclerosis, Relapsing-Remitting

Russian Federation
Merck KGaA, Darmstadt, Germany

Completed

Study To Evaluate The Immunogenicity And Safety Of r-hIFN Beta-1a (Rebif®) Using Clone 484-39 In Multiple Sclerosis

Relapsing Remitting Multiple Sclerosis
Johns Hopkins University
Biogen

Withdrawn

Using Optical Coherence Tomography (OCT) to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Patients With Relapsing Multiple Sclerosis

Relapsing Remitting Multiple Sclerosis
Biogen

Completed

Demonstrate the Bioequivalence of Interferon Beta-1a (INFB) Manufactured by Two Different Processes in Healthy Volunteers

Multiple Sclerosis

United States
Bristol-Myers Squibb

Completed

Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir (PEDESTAL)

Hepatitis C Virus

Belgium, Germany, Spain, United States, Canada, Brazil, Austria, France, Israel, Switzerland, Italy, Russian Federation, Czechia, Poland, United Kingdom
Johns Hopkins University
Eiger BioPharmaceuticals

Terminated

Peginterferon Lambda-1a for the Prevention and Treatment of SARS-CoV-2 (COVID-19) Infection (PROTECT)

Sars-CoV-2 Infection

United States
S. Andrea Hospital

Unknown

Safety and Tolerability of Interferon-Beta-1a and Estroprogestins Association in MS Patients

Multiple Sclerosis

Italy
Merck KGaA, Darmstadt, Germany
Merck spol.s.r.o., Czech Republic

Completed

Post-Authorization Observational Study to Evaluate Cognition and Fatigue in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Treated With Rebif® (SKORE)

Multiple Sclerosis, Relapsing-Remitting

Czech Republic
Merck KGaA, Darmstadt, Germany
Gesellschaft für Therapieforschung mbH

Completed

An Observational Study Evaluating Therapy Optimisation Using High-frequency and High-dosage Administration of Interferon-beta (Rebif®) in Multiple Sclerosis (MS) Patients

Relapsing-Remitting Multiple Sclerosis
Merck KGaA, Darmstadt, Germany
Gesellschaft für Therapieforschung mbH

Completed

An Observational Study to Document the Effectiveness and Compatibility of Rebif 44 or 22 µg in the Therapy of the Chronic Multiple Sclerosis

Multiple Sclerosis

Germany
Biogen

Completed

Safety and Efficacy of Avonex in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Chronic Inflammatory Demyelinating Polyradiculoneuropathy

United States, Australia, Canada, United Kingdom
Merck KGaA, Darmstadt, Germany
Merck Serono Australia Pty Ltd

Completed

Post Marketing Surveillance Study to Evaluate the Tolerability of Rebif® New Formulation in Patients With Relapsing Multiple Sclerosis in an Australian Clinical Setting. (ReNew)

Multiple Sclerosis

Australia
National Institute of Neurological Disorders and...

Completed

Recombinant Human Interferon Beta-1a (Avonex) for the Treatment of Patients With HTLV-1-Associated Myelopathy (HAM)

Tropical Spastic Paraparesis | Spinal Cord Disease | HTLV-I Infection

United States
Biogen

Completed

Open-Label Safety Extension Study of Avonex

Multiple Sclerosis
Biogen

Completed

Pharmacodynamic Study to Better Understand the Therapeutic Response and Immunomodulatory Effects of Avonex in Multiple Sclerosis (MS) Patients and Healthy Volunteers

Multiple Sclerosis
Cinnagen

Completed

Pharmacokinetics and Pharmacodynamics of CinnoVex (Interferon Beta-1a) Compared to Avonex (Interferon Beta-1a)

Healthy | Bioequivalence

Finland
Synairgen Research Ltd.

Completed

Comparing Efficacy and Safety of Inhaled SNG001 to Placebo

Asthma

United Kingdom

Search clinical trials for: Peginterferon beta-1a

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cyprus

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations